Showing results (21-30 of 32) with videos related to

Sort By:
Pageof 4
ACS Infectious Diseases|January 23, 2020
The Q<sub>i</sub> Site of Cytochrome <i>b</i> is a Promiscuous Drug Target in <i>Trypanosoma cruzi</i> and <i>Leishmania donovani</i>Richard J Wall, Sandra Carvalho, Rachel Milne, et al.
Journal of Medicinal Chemistry|August 3, 2010
Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead seriesJose M Coterón, David Catterick, Julia Castro, et al.
European Journal of Medicinal Chemistry|May 20, 2022
Identification and development of a series of disubstituted piperazines for the treatment of Chagas diseaseKate McGonagle, Gary J Tarver, Juan Cantizani, et al.
Journal of Medicinal Chemistry|April 27, 2021
Scaffold-Hopping Strategy on a Series of Proteasome Inhibitors Led to a Preclinical Candidate for the Treatment of Visceral LeishmaniasisMichael Thomas, Stephen Brand, Manu De Rycker, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|November 14, 2025
Immunological Profiling suggests an Association between Treg dysfunction and Pain in Knee OsteoarthritisMarie Binvignat, Johanna Dubois, Maria Marco Salvador, et al.
Science Translational Medicine|December 13, 2023
Short-course combination treatment for experimental chronic Chagas diseaseSilvia González, Richard J Wall, John Thomas, et al.
Science Translational Medicine|December 13, 2023
DNDI-6174 is a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc<sub>1</sub>Stéphanie Braillard, Martine Keenan, Karen J Breese, et al.
Journal of Medicinal Chemistry|August 29, 2017
Discovery and Optimization of 5-Amino-1,2,3-triazole-4-carboxamide Series against Trypanosoma cruziStephen Brand, Eun Jung Ko, Elisabet Viayna, et al.
Pageof 4